Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084722 | 0.96 | HTR1D (0.46) | HTR2AHTR1AHTR6HTR1DCA12 | |
| SCHEMBL27084710 | 0.95 | HTR1A (0.53) | HTR2AHTR1AHTR6HTR1DCA12 | |
| SCHEMBL27085221 | 0.93 | HTR2A (0.55) | HTR2AHTR1AHTR6HTR1DMPO | |
| SCHEMBL27084915 | 0.89 | HTR1A (0.47) | HTR2AHTR1AHTR6HTR1DCA12 | |
| SCHEMBL27084715 | 0.89 | TYR (0.48) | HTR2AHTR1ACA12CA9 | |
| SCHEMBL27084794 | 0.89 | HTR1D (0.54) | HTR2AHTR1AHTR6HTR1DBCHE | |
| SCHEMBL27085096 | 0.89 | HTR6 (0.47) | HTR2AHTR1AHTR6HTR1DCA12 | |
| SCHEMBL27084908 | 0.87 | HTR1A (0.59) | HTR2AHTR1AHTR6HTR1DMPO | |
| SCHEMBL27085239 | 0.87 | HTR6 (0.58) | HTR2AHTR1AHTR6HTR1DCA12 | |
| SCHEMBL27084696 | 0.87 | HTR6 (0.43) | HTR2AHTR1AHTR6HTR1DCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | HTR2A 53/4885HTR1A 181/4885HTR6 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.